Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 2, 2014, Pages 280-289

  Nolan, Terry M ^a   Nissen, Michael D ^b   Naz, Aftab ^c   Shepard, Julie ^d   Bedell, Lisa ^e   Hohenboken, Matthew ^e   Odrljin, Tatjana ^e   Dull, Peter M ^e  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c Madera Family Medical Group   (United States)

^d Ohio Pediatric Research Association   (United States)

^e NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Conjugate vaccine; Immunogenicity; Infants; Meningococcal disease; Safety

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; RECOMBINANT HEPATITIS B VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA-TETANUS-FIVE COMPONENT ACELLULAR PERTUSSIS-INACTIVATED POLIOMYELITIS -HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE; HAEMOPHILUS VACCINE; HEPATITIS B VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; MENACWY-CRM VACCINE; POLIOMYELITIS VACCINE; VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NORMAL HUMAN; OTITIS MEDIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; PROCEDURES; VACCINATION;

DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; TREATMENT OUTCOME; VACCINATION; VACCINES, CONJUGATE;

EID: 84896944286     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27051     Document Type: Article

References (37)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88; PMID:11333996; http://dx.doi. org/10.1056/NEJM200105033441807
2. Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, Harnden A, Mant D, Levin M. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006; 367:397- 403; PMID:16458763; http://dx.doi.org/10.1016/ S0140-6736(06)67932-4 (Pubitemid 43184259)
3. WHO. Meningococcal position paper. Wkly Epidemiol Rec 2002; 44:329-40
4. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook - 12th Edition (April 2011) http://www.cdc.gov/vaccines/ pubs/pinkbook/mening.html Accessed 6 June 2012.
5. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196- 210; PMID:17604802; http://dx.doi.org/10.1016/ S0140-6736(07)61016-2 (Pubitemid 46977462)
6. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Safadi MA. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012; 30(Suppl 2):B26-36; PMID:22178525; http://dx.doi.org/10.1016/j.vaccine.2011.12.032
7. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91; PMID:20001736; http://dx.doi. org/10.1086/649209
8. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-20; PMID:20410516; http://dx.doi.org/10.1056/ NEJMra0906357
9. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009; 28:220-4; PMID:19209096; http://dx.doi.org/10.1097/ INF.0b013e31819040e7
10. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB; Meningococcal Reference Unit. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55:887-96; PMID:16772416; http://dx.doi. org/10.1099/jmm.0.46288-0 (Pubitemid 43974695)
11. Stoddard J, Dougherty N. Universal immunization of infants against Neisseria meningitidis: addressing the remaining unmet medical need in the prevention of meningitis and septicemia. Hum Vaccin 2010; 6:219- 33; PMID:20009513; http://dx.doi.org/10.4161/ hv.6.2.10330
12. Broker M, Cooper B, Detora LM, Stoddard JJ. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease. Infect Drug Resist 2011; 4:137-47; PMID:21904459; http://dx.doi.org/10. 2147/IDR.S12716
13. Gasparini R, Conversano M, Bona G, Gabutti G, Anemona A, Dull PM, Ceddia F. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010; 17:537-44; PMID:20164251; http://dx.doi.org/10.1128/CVI.00436-09
14. Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009; 16:1810-5; PMID:19812260; http://dx.doi.org/10.1128/CVI. 00207-09
15. Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis 2010; 14:e868-75; PMID:20655261; http://dx.doi.org/10.1016/j.ijid.2010.03.017
16. Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010; 28:3171-9; PMID:20189491; http://dx.doi.org/10.1016/j.vaccine.2010.02.045
17. Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:e1-10; PMID:19476428; http://dx.doi.org/10.1086/599117
18. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:657- 63; PMID:19895922; http://dx.doi.org/10.1016/j. vaccine.2009.10.104
19. Halperin SA, Gupta A, Jeanfreau R, Klein NP, Reisinger K, Walter E, Bedell L, Gill C, Dull PM. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:7865-72; PMID:20943209; http://dx.doi.org/10.1016/j.vaccine.2010.09.092
20. Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012; 31:64- 71; PMID:22094635; http://dx.doi.org/10.1097/ INF.0b013e31823dce5c
21. Klein NP, Shepard J, Bedell L, Odrljin T, Dull P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine 2012; 30:3929- 36; PMID:22504039; http://dx.doi.org/10.1016/j. vaccine.2012.03.080
22. Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009; 28:186-93; PMID:19209097; http://dx.doi.org/10.1097/ INF.0b013e31818e037d
23. Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173-84; PMID:18182599; http://dx.doi.org/10.1001/ jama.2007.29-c
24. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27(Suppl 2):B112-6; PMID:19464093; http://dx.doi.org/10.1016/j.vaccine.2009.04.065
25. Tapsall J; Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2007-Amended. Commun Dis Intell Q Rep 2009; 33:1-9; PMID:19618762
26. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, Jolley KA, Maiden MC, Heuberger S, Frosch M. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36; PMID:17168995; http://dx.doi.org/10.1111/j.1574-6976.2006.00060.x (Pubitemid 46058817)
27. Kelly DF, Snape MD, Clutterbuck EA, Green S, Snowden C, Diggle L, Yu LM, Borkowski A, Moxon ER, Pollard AJ. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigenspecific memory B cells. Blood 2006; 108:2642- 7; PMID:16675705; http://dx.doi.org/10.1182/ blood-2006-01-009282
28. Rennels M, King J Jr., Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23:429-35; PMID:15131466; http://dx.doi.org/10.1097/01. inf.0000126297.28952.f8 (Pubitemid 38621482)
29. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 1998; 17(Suppl):S117-22; PMID:9781743; http://dx.doi.org/10.1097/00006454-199809001-00005 (Pubitemid 28460553)
30. Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine 2011; 29:4881-90; PMID:21549783; http://dx.doi.org/10.1016/j. vaccine.2011.04.053
31. Blanchard-Rohner G, Snape MD, Kelly DF, O'Connor D, John T, Clutterbuck EA, Ohene- Kena B, Klinger CL, Odrljin T, Pollard AJ. The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age. Vaccine 2013; 31:2441- 8; PMID:23566945; http://dx.doi.org/10. 1016/j. vaccine.2013.03.036
32. Findlow H, Plikaytis BD, Aase A, Bash MC, Chadha H, Elie C, Laher G, Martinez J, Herstad T, Newton E, et al. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clin Vaccine Immunol 2009; 16:969- 77; PMID:19474264; http://dx.doi.org/10.1128/ CVI.00068-09
33. Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (MenveoR) or MenactraR among healthy adolescents. Hum Vaccin 2010; 6:881-7; PMID:21339701; http://dx.doi.org/10.4161/ hv.6.11.12849
34. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7; PMID:15276396; http://dx.doi.org/10.1016/S0140-6736(04) 16725-1 (Pubitemid 38970013)
35. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. JAMA 2000; 283:2795- 801; PMID:10838647; http://dx.doi.org/10.1001/ jama.283.21.2795 (Pubitemid 30387823)
36. Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 2005; 24:128- 31; PMID:15702040; http://dx.doi.org/10.1097/01. inf.0000151029.58752.27 (Pubitemid 40250770)
37. Blanchard Rohner G, Snape MD, Kelly DF, John T, Morant A, Yu LM, Borkowski A, Ceddia F, Borrow R, Siegrist CA, et al. The magnitude of the antibody and memory B cell responses during priming with a protein- polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 2008; 180:2165-73; PMID:18250423